Scalable Multiplexed Drug‐Combination Screening Platforms Using 3D Microtumor Model for Precision Medicine
Source abstract
Abstract
Abstract Cancer heterogeneity is a notorious hallmark of this disease, and it is desirable to tailor effective treatments for each individual patient. Drug combinations have been widely accepted in cancer treatment for better therapeutic efficacy as compared to a single compound. However, experimental complexity and cost grow exponentially with more target compounds under investigation. The primary challenge remains to efficiently perform a large‐scale drug combination screening using a small number of patient primary samples for testing. Here, a scalable, easy‐to‐use, high‐throughput drug combination screening scheme is reported, which has the potential of screening all possible pairwise drug combinations for arbitrary number of drugs with multiple logarithmic mixing ratios. A “Christmas tree mixer” structure is introduced to generate a logarithmic concentration mixing ratio between drug pairs, providing a large drug concentration range for screening. A three‐layer structure design and special inlets arrangement facilitate simple drug loading process. As a proof of concept, an 8‐drug combination chip is implemented, which is capable of screening 172 different treatment conditions over 1032 3D cancer spheroids on a single chip. Using both cancer cell lines and patient‐derived cancer cells, effective drug combination screening is demonstrated for precision medicine.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: 3D Printing in Biomedical Research · Mathematical Biology Tumor Growth · Cell Image Analysis Techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Electrical Engineering and Computer Science University of Michigan 1301 Beal Avenue Ann Arbor MI 48109‐2122 USA
University of Michigan Comprehensive Cancer Center 1500 E. Medical Center Drive Ann Arbor MI 48109 USA
University of Michigan Health System Ann Arbor MI 48109 USA
Department of Biomedical Engineering University of Michigan Ann Arbor MI 48109 USA
Funding
National Institutes of Health
References (52)
Show source-provided references
1. 10.1038/clpt.2012.23710.1038/clpt.2012.237 ↗
2. 10.1186/s13073-015-0203-x10.1186/s13073-015-0203-x ↗
3. 10.1111/cts.1242910.1111/cts.12429 ↗
4. 10.1038/nrclinonc.2015.12310.1038/nrclinonc.2015.123 ↗
5. Park Y. J. · Epigenet. Dis. · 2010 · 25
6. 10.1038/nrg340410.1038/nrg3404 ↗
7. 10.1016/j.urolonc.2014.03.01110.1016/j.urolonc.2014.03.011 ↗
8. 10.1016/j.drudis.2013.07.00110.1016/j.drudis.2013.07.001 ↗
9. 10.1038/nrd436610.1038/nrd4366 ↗
10. 10.1038/nrd453910.1038/nrd4539 ↗
11. 10.1038/nbt.228410.1038/nbt.2284 ↗
12. 10.1038/bjc.2012.58110.1038/bjc.2012.581 ↗
13. 10.1093/carcin/bgt08610.1093/carcin/bgt086 ↗
14. 10.1016/j.drudis.2006.11.00810.1016/j.drudis.2006.11.008 ↗
15. 10.1038/nrc359910.1038/nrc3599 ↗
16. 10.1002/1097-0142(197501)35:1<98::AID-CNCR2820350115>3.0.CO;2-B10.1002/1097-0142(197501)35:1<98::AID-CNCR2820350115>3.0.CO;2-B ↗
17. 10.1155/2013/13741410.1155/2013/137414 ↗
18. 10.1038/nrd336810.1038/nrd3368 ↗
19. 10.1371/journal.pcbi.100322610.1371/journal.pcbi.1003226 ↗
20. US Food and Drug Administration Guidance for Industry: Codevelopment of Two or More New Investigational Drugs for Use in Combination 2013 1.
21. 10.1073/pnas.131184611110.1073/pnas.1311846111 ↗
22. 10.1089/adt.2008.15010.1089/adt.2008.150 ↗
23. 10.1021/ac400688f10.1021/ac400688f ↗
24. 10.1016/j.coche.2014.12.00110.1016/j.coche.2014.12.001 ↗
25. 10.1039/C6LC00062B10.1039/C6LC00062B ↗
26. 10.1039/c2lc21202a10.1039/c2lc21202a ↗
27. 10.4062/biomolther.2014.07810.4062/biomolther.2014.078 ↗
28. Tallarida R. · 2012
29. 10.1039/b417651k10.1039/b417651k ↗
30. 10.1021/ac201177g10.1021/ac201177g ↗
31. 10.1016/j.addr.2013.07.00410.1016/j.addr.2013.07.004 ↗
32. 10.3390/ijms1603551710.3390/ijms16035517 ↗
33. 10.1007/s12079-011-0132-410.1007/s12079-011-0132-4 ↗
34. 10.1039/C6LC00081A10.1039/C6LC00081A ↗
35. 10.1103/PhysRevE.71.05730110.1103/PhysRevE.71.057301 ↗
36. 10.1097/PPO.0b013e31813c117410.1097/PPO.0b013e31813c1174 ↗
37. 10.1002/1097-0142(19860101)57:1<29::AID-CNCR2820570108>3.0.CO;2-L10.1002/1097-0142(19860101)57:1<29::AID-CNCR2820570108>3.0.CO;2-L ↗
38. 10.1186/s12885-016-2052-410.1186/s12885-016-2052-4 ↗
39. 10.1097/MCG.0b013e3181cda09710.1097/MCG.0b013e3181cda097 ↗
40. 10.4161/cbt.5.10.315210.4161/cbt.5.10.3152 ↗
41. 10.4081/oncol.2014.25610.4081/oncol.2014.256 ↗
42. 10.1093/ajhp/54.2.16210.1093/ajhp/54.2.162 ↗
43. 10.1016/j.addr.2014.09.00910.1016/j.addr.2014.09.009 ↗
44. https://www.fda.gov/ Center for drug evaluation and research application number: 207793Orig1s000.
45. 10.1158/0008-5472.CAN-06-203010.1158/0008-5472.CAN-06-2030 ↗
46. 10.1002/jbm.1000510.1002/jbm.10005 ↗
47. 10.1038/srep1217510.1038/srep12175 ↗
48. 10.1002/sim.300510.1002/sim.3005 ↗
49. 10.1002/prp2.14910.1002/prp2.149 ↗
50. 10.1021/jp405593u10.1021/jp405593u ↗
51. 10.1016/j.trecan.2015.11.00310.1016/j.trecan.2015.11.003 ↗
52. 10.1038/nrc195110.1038/nrc1951 ↗